In 2020, as many as 5.8 million Americans were living with Alzheimer’s Disease (AD)—a number projected to nearly triple to 14 million people by 2060. 1 As changes in the brain can begin years before ...

Biomarkers hold the key to more targeted and timely patient care, yet current tools for analyzing and identifying them often fall short in specificity, sensitivity, or scalability. The complexity of ...

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...

In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...